haylaavo

SHARONBIO

SHARONBIO · NSE · inactive
3.30
-0.15 (-4.35%)
as of 28 Mar 2019 close
Open
3.30
High
3.30
Low
3.30
Prev close
3.45
52w high
7.40
14 Sept 2018
52w low
2.75
06 Aug 2018
VWAP
3.30
Delivery %
—
n/a
Volume 8,834 · turnover ₹29,152 · NSE bhavcopy (official close), adjusted for splits/bonuses · history since 07 Dec 2011
Series
BZ
F&O
No
Status
Inactive since 29 Mar 2019

Source: NSE equity master · as of 28 Mar 2019

Daily · NSE EOD
Exchange announcements
Source: NSE corporate filings · latest Today 03:56 IST
  • 21 Nov 2014 12:37
    Dividend

    Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on November 21, 2014 has resolved and recommended final dividend @ 18% which amounts to Rs. 0.36/- per equity share of Rs. 2 each for the Financial Year ended June 30, 2014.

  • 21 Nov 2013 16:24
    Dividend

    Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors of the Company at the Meeting held on November 14, 2013 has recommended dividend of Rs.1.50/- per share on 10556900 equity shares of Rs.10/- each fully paid up for the year ended 2012-13, subject to approval of the members at the ensuing Annual General Meeting.

  • 21 Nov 2013 16:20
    Dividend

    Sharon Bio-Medicine Limited has informed the Exchange that the dividend shall be paid on January 06, 2014.

  • 22 Oct 2012 18:47
    Dividend

    Sharon Bio-Medicine Limited has informed the Exchange that Board of Directors of the Company at the Meeting held on October 22, 2012 had resolved and recommended dividend @ Rs. 1.80 per share subject to approval of shareholders at the Annual General Meeting.

  • 07 Dec 2011 13:25
    Dividend

    Sharon Bio-Medicine Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on October 24, 2011, concluded the following:- (1) Recommendation of Dividend of Rs.1.80/- per share on 10556900 equity shares of Rs.10/- each fully paid up for the year ended June 30, 2011, subject to approval of the members at the ensuing Annual General Meeting.

Coming next in news
Arrives in Phase 3. Nothing here is estimated or filled in — we only show data we have.
  • Results & board-meeting calendar
  • Dividend, split, AGM calendar
  • Headlines with source and timestamp
  • Two-line factual filing summaries